DDOG vs PFE: Which Is the Better Buy?

Side-by-side comparison of Datadog, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Datadog, Inc. · Technology
$104.77
+55.6% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
DDOG has more upside to fair value (+55.6%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric DDOG PFE
Current Price $104.77 $26.91
Fair Value Estimate $163.01 $35.00
Upside to Fair Value +55.6% +30.1%
Market Cap $37.1B $153.0B
Forward P/E 341.2x 9.5x
EV / EBITDA 168.3x 13.8x
Price / Sales 10.8x 2.4x
Price / FCF 37.0x 16.8x
Revenue Growth YoY +7.6% -1.6%
Gross Margin 79.9% 70.3%
Operating Margin -1.3% 24.7%
Return on Equity 3.2% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 2.7% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
DDOG — Datadog, Inc.
Datadog, Inc. is a leading cloud-based monitoring and analytics platform specializing in observability and security for cloud-native, microservices, and AI applications. The company benefits from strong product-market fit driven by extensive integrations and a customer-centric approach, reflected in 26% revenue growth to $3.43 billion in fiscal 2025 and 37.4% earnings growth year-over-year. Despi…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric DDOG PFE
Zone Low $122.26 $25.00
Zone High $138.56 $29.00
In Buy Zone? Yes Yes
← DDOG Research    PFE Research →    All Research